Eli Lilly and Company (NYSE:LLY) Shares Purchased by N.E.W. Advisory Services LLC

Key Points

• N.E.W. Advisory Services LLC raised its stake in Eli Lilly and Company by 48.3% during the first quarter, bringing its total holdings to 1,060 shares valued at $876,000.
• The company recently reported quarterly earnings of $3.34 EPS, falling short of analysts' expectations of $4.64, with revenue reaching $12.73 billion, up 45.2% year-over-year.
• Eli Lilly declared a quarterly dividend of $1.50 per share, which will be paid on September 10th, reflecting a dividend yield of 0.74% based on a payout ratio of 48.82%.

N.E.W. Advisory Services LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 48.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,060 shares of the company's stock after buying an additional 345 shares during the period. N.E.W. Advisory Services LLC's holdings in Eli Lilly and Company were worth $876,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Geode Capital Management LLC boosted its holdings in Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after acquiring an additional 291,875 shares during the period. GAMMA Investing LLC increased its holdings in shares of Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Capital Research Global Investors grew its holdings in Eli Lilly and Company by 16.1% during the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after acquiring an additional 1,493,673 shares during the period. Finally, Northern Trust Corp grew its holdings in Eli Lilly and Company by 14.6% during the 4th quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock worth $7,294,025,000 after acquiring an additional 1,204,337 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LLY has been the subject of several research reports. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, Morgan Stanley reissued an "overweight" rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Stock Down 0.4%

Shares of LLY traded down $3.19 during mid-day trading on Wednesday, reaching $759.76. The company had a trading volume of 4,331,834 shares, compared to its average volume of 3,787,427. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a 50-day moving average price of $773.36 and a 200 day moving average price of $800.41. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a market capitalization of $720.05 billion, a price-to-earnings ratio of 61.82, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.79%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.